{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218290","form_type":"8-K/A","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2026-05-12T12:56:29+00:00","discovered_at":"2026-05-12T13:00:00.289594+00:00","generated_at":"2026-05-12T13:05:41.296341+00:00","sec_items":["2.02","2.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Mereo BioPharma Q1 net loss $6.7M; setrusumab Phase 3 fails primary endpoint, regulator engagement begun","bullets":["Net loss of $6.7M in Q1 2026 vs $12.9M in Q1 2025; cash and equivalents $36.2M as of March 31, 2026.","Setrusumab Phase 3 studies in OI did not meet primary fracture-rate endpoints; high significance on BMD, vertebral fracture reduction, and PROs.","Mereo and partner Ultragenyx initiated regulatory discussions for pediatric OI path; no approved therapies exist.","Alvelestat partnership discussions active; single Phase 3 trial of ~220 patients with SGRQ (US) and lung density (EU) endpoints planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218290","json":"https://secwatch.observer/filing/0001193125-26-218290.json","markdown":"https://secwatch.observer/filing/0001193125-26-218290.md","text":"https://secwatch.observer/filing/0001193125-26-218290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526218290/0001193125-26-218290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526218290/mreo-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T13:05:41.296341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59561c847f96a772b7dc15cf116210aab3cbe82b","claim":"Mereo BioPharma Group plc reported first quarter ended March 31, 2026 results: net income $6.7 million. Guidance reaffirmed.","evidence_excerpt":"Net loss for the first quarter of 2026 was $6.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526218290/0001193125-26-218290-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"$6.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}